ESC 365 - Long-term safety and efficacy of sodium zirconium cyclosilicate (ZS-9) in the treatment of hyperkalaemia: interim analysis of ZS-005, an open-label phase 3 study

HFA Premium Access

Long-term safety and efficacy of sodium zirconium cyclosilicate (ZS-9) in the treatment of hyperkalaemia: interim analysis of ZS-005, an open-label phase 3 study

Session: Clinical Forum - Mon. 23 May 08:30 - Tues. 24 May 12:30

Topic: Drug therapy, other

Speaker: Professor S. Anker (Berlin, DE)

Event: HEART FAILURE 2016

Congress Presentation

Add to my library

About the speaker

Professor Stefan Anker

Charite University Hospital, Berlin (Germany)

171 presentations

11 followers

22 more presentations in this session

Zofenopril combined with xanthine oxidase inhibitors may improve survival in post-myocardial infarction patients as compared to placebo or other ACE-inhibitors

Long-term effects and sustainability of collaborative disease management in systolic heart failure - the extended interdisciplinary network heart failure study

Speaker: Professor C. Angermann (Wurzburg, DE)

An implantable pressure sensor for long-term wireless monitoring of cardiac function -first study in man

Speaker: Doctor J. Baranowski (Linkoping, SE)

Heart failure hospitalisation or cardiovascular death with empagliflozin in patients with type 2 diabetes and high cardiovascular risk: analysis over time in EMPA-REG OUTCOME

Speaker: Doctor D. Fitchett (Toronto, CA)

Characteristics of myocardial deformation parameters and their prognostic impact in patients with hypertrophic cardiomyopathy: a speckle tracking imaging analysis

Speaker: Doctor S. Charfeddine (Sfax, TN)

Access the full session

Clinical Forum - Mon. 23 May 08:30 - Tues. 24 May 12:30

Speakers: Professor S. Anker, Professor C. Angermann, Doctor J. Baranowski, Doctor D. Fitchett, Doctor S. Charfeddine

About the event

HEART FAILURE 2016

21 May - 24 May 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources